Published research on Eloralintide: record counts, recent publications, reviews and registered studies, pulled from PubMed and ClinicalTrials.gov. Part of metabolic research.
Ask TinaTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Registered studies by status: 11 recruiting, 3 active not recruiting, 3 completed.
Number of PubMed records mentioning Eloralintide, 2016 to 2026 (2026 is year to date).
Most recently started of 18 ClinicalTrials.gov entries.
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07765511 · Not Yet Recruiting · Phase 1 · started 2026-10A Study of Eloralintide (LY3841136) in Female Participants With Obesity or OverweightNCT07808060 · Recruiting · Phase 1 · started 2026-09-15A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightNCT07738614 · Recruiting · Phase 1 · started 2026-07-31A Study of Eloralintide (LY3841136) in Healthy ParticipantsNCT07701083 · Active Not Recruiting · Phase 1 · started 2026-07-20A Study of Eloralintide (LY3841136) in Participants With Overweight or ObesityNCT07665879 · Recruiting · Phase 1 · started 2026-06-24A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightNCT07589608 · Recruiting · Phase 2 · started 2026-05-15A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionNCT07426380 · Active Not Recruiting · Phase 1 · started 2026-02-24A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 · Recruiting · Phase 3 · started 2026-02-10A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011 · Recruiting · Phase 3 · started 2026-02-10A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.NCT07401862 · Recruiting · Phase 1 · started 2026-02-10Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931 · Recruiting · Phase 3 · started 2026-02-09A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 · Recruiting · Phase 3 · started 2026-02-06Primary data for your own interpretation: published studies and regulator documents. No publisher opinion pieces.
Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.Pharmacol Res · 2026 Aug 12 · Fischer SL et al. · PubMedCardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide.Cardiol Rev · 2026 Sep 16 · Sigalov A et al. · PubMedObesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.Metabol Open · 2026 Mar 23 · Lempesis IG et al. · PubMedAsk Tina for links to further coverageTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Third-party links, listed for reference. Educational information only, not medical advice. Hypnotic Dose does not endorse any product.